Accessibility Menu
Northwest Biotherapeutics logo

Northwest Biotherapeutics(OTC) NWBO

Current Price$0.17
Market Cap$298.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)-100%
5 Year-87%
1 Year-33%
1 Month-9%
Northwest Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.182026-07-20
Northwest Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.83%USD 0.182026-07-13
1 month-8.95%USD 0.192026-06-18
3 month-9%USD 0.192026-04-21
Year to date-22.62%USD 0.232025-12-31
1 year-33.14%USD 0.262025-07-18
3 year-67.22%USD 0.542023-07-21
5 year-87.08%USD 1.372021-07-21
Since inception-99.99%USD 1,274.532001-12-14

Northwest Biotherapeutics Financials at a Glance

Market Cap

$298.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.50M

Net Income (TTM)

-$43.89M

EPS (TTM)

-$0.03

P/E Ratio

-5.78

Dividend

$0.00

Beta (Volatility)

0.05 (Low)

Price

$0.17

Volume

1,959,210

Open

$0.18

Previous Close

$0.18

Daily Range

$0.17 - $0.18

52-Week Range

$0.14 - $0.37

Estimated Earnings Date

Aug 13, 2026

NWBO News

GettyImages-956478192

Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?

Zhiyuan SunOct 28, 2020
GettyImages-1138086580

Did Northwest Biotherapeutics Just Check Off 1 Box Needed for Its Stock to Double?

Zhiyuan SunMay 28, 2020
X

Why Northwest Biotherapeutics, Accuray, and U.S. Steel Slumped Today

Dan CaplingerDec 23, 2015
Image by PeteLinforth via Pixabay

5 Stocks We're Staying Away From in 2016

Brian FeroldiDec 20, 2015

3 Stocks I Would Avoid at All Costs

Steve SymingtonNov 16, 2015
NWBO-Pipeline2

Why Shares of Northwest Biotherapeutics Inc Are Crashing Today

Brian FeroldiAug 21, 2015
afrezza

2 Biotech Stocks Wall Street Hates

George Budwell, PhDAug 15, 2015
doctor patient consultation

This Illegal Drug Could Be the Answer to Fighting Brain Cancer

Sean WilliamsDec 14, 2014
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Northwest Biotherapeutics

Northwest Biotherapeutics develops therapies that help the body fight cancer. Its main products aim to support patients with aggressive brain tumors and inoperable cancers. The company’s work focuses on using the immune system to target disease.

What’s in the Northwest Biotherapeutics Toolbox?

  • DCVax-L: Personalized therapy for operable brain tumors, especially glioblastoma; no material revenue contribution yet.
  • DCVax-Direct: Treatment for inoperable solid tumors; in early clinical trials, not yet generating revenue.
  • Manufacturing Services: Production of DCVax products through contract partners; revenue not separately disclosed.
  • Compassionate Use Programs: Access to therapies for patients outside clinical trials; revenue impact minimal.
  • In-licensed Technologies: Developing new manufacturing capabilities for future products; no current revenue.

Growth and Expansion: The Road So Far

  • Submitted UK marketing application for DCVax-L in December 2023.
  • Expanded UK manufacturing with Advent BioServices through ongoing facility upgrades in Sawston and London.
  • Restarted DCVax-Direct program in 2025 with new manufacturing milestones.
  • Developing US manufacturing for in-licensed technologies; contract talks ongoing in 2025.
  • Expanded compassionate use programs in the UK with additional clinics and doctors.

What Makes Northwest Biotherapeutics Stand Out?

The company specializes in personalized cancer immunotherapy, using a patient’s own immune cells. It operates dedicated manufacturing sites in the UK, supporting clinical and early access programs. Strategic partnerships help manage production and process development for future therapies.

Five Things You Need to Know

  • Revenue was $131,000 in Q2 2025, down 74.3% from Q2 2024.
  • Net loss was $15.4 million in Q2 2025, improving 13.9% year-over-year.
  • Cash used in operations was $16.1 million for the six months ended June 2025, compared to $28.6 million for the same period in 2024.
  • Cash and equivalents were $4.3 million as of June 30, 2025.
  • Company had 25 full-time employees and $1.48 billion accumulated deficit as of June 2025.

Bottom Line

Northwest Biotherapeutics focuses on personalized cancer therapies and faces ongoing financial challenges. Its future depends on regulatory progress and successful commercialization of its lead products.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

25

CEO

Linda F. Powers

Website

www.nwbio.com

Headquarters

Bethesda, MD 20814, US

NWBO Financials

Key Financial Metrics (TTM)

Gross Margin

-44.89%

Operating Margin

-3574.01%

Net Income Margin

-2931.73%

Return on Equity

62.41%

Return on Capital

-347.19%

Return on Assets

-54.83%

Earnings Yield

-17.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$298.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.69B

Volume

1.96M

Avg. Volume

3.71M

Financials (TTM)

Gross Profit

-$672.00K

Operating Income

-$53.50M

EBITDA

-$59.83M

Operating Cash Flow

-$47.85M

Capital Expenditure

-$433.00K

Free Cash Flow

-$48.29M

Cash & ST Invst.

$1.79M

Total Debt

$63.99M

Northwest Biotherapeutics Performance Analysis

Northwest Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,683,00067.5%
20232023-12-31USD 1,932,00014.8%
20242024-12-31USD 1,382,000-28.5%
20252025-12-31USD 1,378,000-0.3%
Northwest Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-65.1%
Q32025-09-3052.7%
Q42025-12-31236.0%
Q12026-03-31-26.5%
Northwest Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.1072.9%
20232023-12-31USD -0.06-44.4%
20242024-12-31USD -0.0719.3%
20252025-12-31USD -0.04-38.5%
Northwest Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.9%
Q32025-09-30-64.0%
Q42025-12-31104.9%
Q12026-03-31-333.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$494.00K

+31.7%

Gross Profit

-$353.00K

-194.1%

Gross Margin

-71.46%

N/A

Market Cap

$298.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.85M

N/A

Employees

105

N/A

Net Income

-$3.07M

+84.3%

EBITDA

-$10.05M

+41.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.79M

-35.7%

Total Debt

$63.99M

-7.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$20.50M

-16.6%

Short Term Debt

$43.77M

-1.5%

Return on Assets

-54.83%

N/A

Return on Invested Capital

18.31%

N/A

Free Cash Flow

-$12.64M

-34.2%

Operating Cash Flow

-$12.51M

-32.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYDYCytoDyn Inc.
$0.20-0.97%
CMVLFCellectis S.A.
$3.47+12.66%
PTCHFPureTech Health plc
$1.60+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.09+0.01%
MARAMara Holdings
$12.39+0.06%
UTZUtz Brands
$14.09+0.89%
HLHecla Mining
$15.32+0.07%

Questions About NWBO

What is the current price of Northwest Biotherapeutics?

Northwest Biotherapeutics is trading at $0.17 per share.

What is the 52-week range for Northwest Biotherapeutics?

Over the past 52 weeks, Northwest Biotherapeutics has traded between $0.14 and $0.37.

How much debt does Northwest Biotherapeutics have?

As of the most recent reporting period, Northwest Biotherapeutics reported total debt of $63.99M.

How much cash does Northwest Biotherapeutics have on hand?

Northwest Biotherapeutics reported $1.79M in cash and cash equivalents in its most recent financial results.

What is Northwest Biotherapeutics’s dividend yield?

Northwest Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services